Boehringer Ingelheim Acquires Fourth License For The Development Of Novel Antibody Based Cancer Treatments From Oxford Biotherapeutics
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of im ...